![](https://library.celltelligence.com/wp-content/uploads/2021/10/TCR2-Tx_BMS_Partnership.png)
$0
Thoughts on TCR2 Tx’s Collaboration With BMS
On Monday, October 25, TCR2 Therapeutics announced (press release) a clinical trial collaboration with BMS to evaluate gavo-cel (TC-210; mesothelin TRuC-T) with Opdivo (nivolumab; PD1 inhibitor) ± Yervoy (ipilimumab; CTLA-4 inhibitor) in a Ph2 trial for refractory mesothelin-expressing solid tumors. Below, Celltelligence provides insights on why TCR2 Tx may have chosen BMS’s checkpoint inhibitors and how BMS could leverage this collaboration for their own solid tumor programs.